๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Southeast Asia Dose Optimization of Tafenoquine

RecruitingPhase 4Ages 2 Years - anyAllUniversity of Oxford
NCT04704999 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoq

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients with symptomatic P. vivax mono-infection as diagnosed by microscopy * Fever or history of fever in the previous 7 days * Quantitative G6PD activity โ‰ฅ70% of the population median * Weight \>10 kg and โ‰ฅ2 years old * Ability to understand the study instructions and provide written informed consent. * Willing to be followed for 4 months Exclusion Criteria: * Pregnancy * Lactation * Hb \< 8 g/dL * Severe malaria * Blood transfusion in the last 4 months * History of allergic response to an 8-aminoquinoline or the nationally recommended schizonticide (e.g., chloroquine, artemether-lumefantrine) * Any previous history of a haemolytic event Presence of any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study (e.g. chronic disease, medications that potentiate or inhibit CYP2D6 or CYP2C8 isoenzyme function)
๐Ÿ’Š

What it tests

  • Tafenoquine
  • Chloroquine
  • Artemether 20 mg-Lumefantrine 120 mg
  • Primaquine
  • Dihydroartemisinin 40 mg-Piperaquine 320 mg
๐Ÿ“

Where

6 sites
Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia
Siem Reap, Cambodia
Oxford University Clinical Research Unit (OUCRU-Indonesia)
Jayapura, Indonesia
Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
Vientiane, Laos
Mahidol Vivax Research Unit (MVRU)
Bangkok, Thailand
Shoklo Malaria Research Unit (SMRU)
Bangkok, Thailand
Oxford University Clinical Research Unit (OUCRU)
Bรฌnh Phฦฐแป›c, Vietnam
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy